PRB2 and autoimmune polyendocrinopathy: In addition, anti-β2GPI-D1 antibodies, along with other non-criteria aPLs, such as anti-phosphatidylserine/prothrombin (anti-PS/PT) antibodies, have shown promising clinical utility in identifying patients with APS and improving risk stratification.